GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
Rhea-AI Summary
GRI Bio (NASDAQ: GRI) will participate in A.G.P.’s Annual Healthcare Company Showcase via a virtual fireside chat on Wednesday, May 20, 2026. CEO Marc Hertz, PhD, will discuss the company’s immune-modulating NKT cell pipeline targeting inflammatory, fibrotic and autoimmune diseases.
A live webcast will be available on the Events page in the Investors section of gribio.com.
Positive
- None.
Negative
- None.
News Market Reaction – GRI
In the May 18 session, GRI gained 5.42%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.2% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Earnings and clinical | Positive | -4.9% | Q1 2026 results and positive Phase 2a IPF data for GRI-0621. |
| Apr 08 | Patent allowance | Positive | +4.3% | UAE Notice of Allowance for dNKT agonist patent in inflammatory conditions. |
| Feb 17 | Clinical data discussion | Positive | +0.0% | CEO segment highlighting additional positive Phase 2a IPF biomarker data. |
| Feb 05 | Investor webinar | Neutral | -17.1% | Announcement of Corporate Connect webinar with pipeline and corporate update. |
| Feb 04 | Earnings and funding | Positive | +1.5% | FY 2025 results, cash build to fund operations into Q1 2027, pipeline progress. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows frequent negative or muted price reactions to fundamentally positive or neutral updates, including clinical data, earnings, and investor events.
Over the past six months, GRI Bio has reported several milestones, including positive Phase 2a IPF data, strengthened cash balances to fund operations into Q2 2027, and regional IP expansion in the UAE. Yet, news like Q1 2026 results on May 14 and the February Webull webinar drew negative reactions, while patent progress on April 8 was better received. Today’s investor showcase appearance fits a pattern of ongoing outreach as the company advances its immune‑modulating pipeline.
Key Terms
natural killer t medical
idiopathic pulmonary fibrosis medical
phase 2a medical
at-the-market stock offering financial
form s-3 regulatory
reverse stock split financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026
Register for the event here
LA JOLLA, CA, May 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will participate in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase being held virtually on Wednesday, May 20, 2026.
Management will discuss the Company’s differentiated immune-modulating pipeline, including progress across its inflammatory, fibrotic and autoimmune disease programs.
Click here to register for the event. A live webcast of the fireside chat will be accessible on the Events page under the Investors section of the Company’s website (gribio.com).
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an RARβ/γ-selective agonist shown to inhibit the activity of key immune cells, such as iNKT cells, and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions. These forward-looking statements are based on the Company’s current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the Company’s expectations with respect to development and commercialization of the Company’s product candidates, the timing of initiation or completion of clinical trials and availability of resulting data, the potential benefits and impact of the Company’s clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies, topline or interim data or trials will be indicative of results of later studies or clinical trials or final data, the Company’s beliefs and expectations regarding potential shareholder value and future financial performance, the Company’s beliefs about the timing and outcome of regulatory approvals and potential regulatory approval pathways, the Company’s expected future milestones, shareholder value and the length of time the Company’s current resources will fund its planned operations (which current estimate assumes only initial preparatory activities for GRI-0621 as substantial additional capital or resources will be required to fund a Phase 2b clinical trial of GRI-0621). Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation risks related to: (1) the Company’s inability to maintain the listing of the Company’s common stock on The Nasdaq Capital Market and to comply with applicable listing requirements; (2) changes in applicable laws or regulations; (3) the inability of the Company to raise financing in the future; (4) the success, cost and timing of the Company’s product development activities; (5) the inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product; (6) the inability of the Company to identify, in-license or acquire additional technology; (7) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (8) the accuracy of the estimated size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; (9) that later data or clinical trials may be inconsistent with or contrary to data and observations to date, including that later data may not indicate a patient benefit, modulate toxicities or validate a mechanism of action; (10) inaccuracy in the Company’s estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing; (11) the Company’s ability to protect and enforce its intellectual property portfolio, including any newly issued patents and its ability to obtain any expected patent term extensions, adjustments, exclusivities or disclaimers; and (12) other risks and uncertainties indicated from time to time in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the risks and uncertainties described in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K filed with the SEC on January 30, 2026 and subsequently filed reports. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
